{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:22:28Z","timestamp":1785799348592,"version":"3.56.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to examine the relationship between the triglyceride-glucose index (TyG) and sarcopenia in patients with chronic kidney disease (CKD). The aim was to gain new insights into preventing and treating sarcopenia in CKD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study utilized data from two cohorts, including the NHANES 2011\u20132018 cohort in the United States and the 2018\u20132023 cohort in China. After applying uniform inclusion and exclusion criteria, 827 patients with CKD in the US cohort and 1,038 patients with CKD in the Chinese cohort were ultimately included in the study. The relationship between the TyG index and sarcopenia was analyzed using logistic regression modeling and multivariate adjustment. The dose-response relationship was also explored using restricted cubic spline (RCS) modeling. Subgroup analyses were also conducted to investigate the potential heterogeneity among different characteristic subgroups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The TyG index was found to be significantly and positively associated with sarcopenia in patients with CKD in both the United States and Chinese cohorts. In the US cohort, the risk of sarcopenia was increased 4.01-fold in the highest TyG quartile group compared with the lowest quartile group (P=0.002). In the Chinese cohort, the corresponding risk was increased 3.25-fold (P&amp;lt;0.001). Furthermore, the RCS analysis corroborated the nonlinear positive association. Subgroup analyses revealed that the correlation between TyG and sarcopenia was more pronounced in patients without diabetes and without metabolic syndrome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The TyG index may serve as a potential biomarker for assessing sarcopenia in CKD patients, thereby supporting the critical role of insulin resistance in developing sarcopenia. Further research is required to elucidate the precise mechanisms by which TyG is associated with sarcopenia and to develop tailored intervention strategies for different patient groups.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1626241","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T04:13:22Z","timestamp":1758168802000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Association between triglyceride-glucose index and sarcopenia in patients with chronic kidney disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Yifen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"2024 Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1161\/CIRCRESAHA.123.322806","article-title":"Increased risk of cardiovascular complications in chronic kidney disease: introduction to a compendium","volume":"132","author":"Noels","year":"2023","journal-title":"Circ Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"sfae205","DOI":"10.1093\/ckj\/sfae205","article-title":"Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance","volume":"17","author":"Dasgupta","year":"2024","journal-title":"Clin Kidney J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S88","DOI":"10.1053\/j.jrn.2022.09.009","article-title":"Muscle atrophy in CKD: A historical perspective of advancements in its understanding","volume":"33","author":"Price","year":"2023","journal-title":"J Ren Nutr"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31465-5","article-title":"Sarcopenia","volume":"393","author":"Cruz-Jentoft","year":"2019","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41572-024-00550-w","article-title":"Sarcopenia","volume":"10","author":"Sayer","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-020-00840-y","article-title":"Sarcopenia in chronic kidney disease: what have we learned so far","volume":"34","author":"Sabatino","year":"2021","journal-title":"J Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13425","article-title":"Prevalence of sarcopenia in patients with chronic kidney disease: a global systematic review and meta-analysis","volume":"15","author":"Duarte","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2022.03.025","article-title":"Association between sarcopenia and clinical outcomes in chronic kidney disease patients: A systematic review and meta-analysis","volume":"41","author":"Ribeiro","year":"2022","journal-title":"Clin Nutr"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0288","article-title":"The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp","volume":"95","author":"Guerrero-Romero","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(22)00247-1","article-title":"Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study","volume":"4","author":"Lopez-Jaramillo","year":"2023","journal-title":"Lancet Healthy Longev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12933-024-02343-7","article-title":"Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease","volume":"23","author":"Chen","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12933-022-01511-x","article-title":"Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations","volume":"21","author":"Tao","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"112419","DOI":"10.1016\/j.exger.2024.112419","article-title":"Association between Triglyceride-glucose index and sarcopenia in China: A nationally representative cohort study","volume":"190","author":"Chen","year":"2024","journal-title":"Exp Gerontol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12944-024-02201-1","article-title":"The association between the triglyceride-glucose index and sarcopenia: data from the NHANES 2011-2018","volume":"23","author":"Yang","year":"2024","journal-title":"Lipids Health Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2014.112","article-title":"Mechanisms of muscle wasting in chronic kidney disease","volume":"10","author":"Wang","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4350","article-title":"Insulin action and resistance in obesity and type 2 diabetes","volume":"23","author":"Czech","year":"2017","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s13098-024-01536-0","article-title":"The systemic immune-inflammation index and systemic inflammation response index are useful for predicting mortality in patients with diabetic nephropathy","volume":"16","author":"Zhang","year":"2024","journal-title":"Diabetol Metab Syndr"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glu010","article-title":"The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates","volume":"69","author":"Studenski","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00340.2016","article-title":"Insulin resistance in chronic kidney disease: a systematic review","volume":"311","author":"Spoto","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11892-018-1010-8","article-title":"Chronic kidney disease-induced insulin resistance: current state of the field","volume":"18","author":"Dave","year":"2018","journal-title":"Curr Diabetes Rep"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000700","article-title":"New insights into muscle function in chronic kidney disease and metabolic acidosis","volume":"30","author":"Chalupsky","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.3390\/nu13124349","article-title":"Role and treatment of insulin resistance in patients with chronic kidney disease: A review","volume":"13","author":"Nakashima","year":"2021","journal-title":"Nutrients"},{"key":"B29","doi-asserted-by":"publisher","first-page":"115407","DOI":"10.1016\/j.bcp.2022.115407","article-title":"Chronic kidney disease-induced muscle atrophy: Molecular mechanisms and promising therapies","volume":"208","author":"Wang","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/978-981-13-1435-3_18","article-title":"Muscle atrophy in chronic kidney disease","volume":"1088","author":"Schardong","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/toxins14040263","article-title":"Methylglyoxal induces inflammation, metabolic modulation and oxidative stress in myoblast cells","volume":"14","author":"Todoriki","year":"2022","journal-title":"Toxins (Basel)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12791","article-title":"Resistance exercise and nutritional interventions for augmenting sarcopenia outcomes in chronic kidney disease: a narrative review","volume":"12","author":"Noor","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.3390\/nu15143107","article-title":"Nutritional strategies to prevent muscle loss and sarcopenia in chronic kidney disease: what do we currently know","volume":"15","author":"Massini","year":"2023","journal-title":"Nutrients"},{"key":"B34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12877-022-02916-9","article-title":"Diabetes, sarcopenia and chronic kidney disease; the Screening for CKD among Older People across Europe (SCOPE) study","volume":"22","author":"Formiga","year":"2022","journal-title":"BMC Geriatr"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1626241\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T04:13:23Z","timestamp":1758168803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1626241\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":34,"alternative-id":["10.3389\/fendo.2025.1626241"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1626241","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"article-number":"1626241"}}